| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Divisions of Endocrinology, Diabetes, and Clinical Nutrition (J.J.P., S.V., M.K., U.K., B.M.) and Gynecological Endocrinology and Reproductive Medicine (C.D.G.), University Hospital, CH-4031 Basel, Switzerland
Address all correspondence and requests for reprints to: Jardena J. Puder, Division of Endocrinology, Diabetes, and Clinical Nutrition, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland. E-mail: Puderj{at}uhbs.ch.
Background: It is controversial whether the polycystic ovary syndrome (PCOS) per se increases low-grade chronic inflammation and whether this relates to central fat excess. In addition, the association between circulating sex hormones and body fat distribution in premenopausal women is debated.
Methods: Blood was drawn from 20 patients with PCOS and compared with 15 controls, matched for body mass index and age. Regional fat distribution was assessed using dual x-ray absorptiometry.
Results: Compared with controls, patients with PCOS had a higher trunk to extremity fat ratio (T/E fat), were more insulin resistant (higher homeostasis model assessment of insulin resistance and lower SHBG concentrations), and had higher levels of highly sensitive C-reactive protein, TNF-
, procalcitonin, and white blood cell count (all P 
0.04), even after adjusting for total body fat. However, additional adjusting for T/E fat eliminated or attenuated the effect of PCOS status on estimates of insulin resistance, on inflammatory mediators, and on white blood cell count but not on circulating sex hormones. Independently of each other, total body fat as well as T/E fat correlated with estimates of insulin resistance and most inflammatory mediators (P 0.04). However, the correlations between T/E fat and circulating sex hormones (P 0.02) were greatly reduced after adjustment for the presence of PCOS.
Conclusion: The increase in low-grade chronic inflammation and in insulin resistance in women with PCOS is primarily associated with increased central fat excess rather than PCOS status per se. Procalcitonin represents a novel marker of the inflammatory activity of body fat and of PCOS.
This article has been cited by other articles:
 |
|
 |
|
  P. F. Svendsen, L. Nilas, K. Norgaard, J.-E. B. Jensen, and S. Madsbad Obesity, body composition and metabolic disturbances in polycystic ovary syndrome Hum. Reprod., September 1, 2008; 23(9): 2113 - 2121. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.O. Goodarzi, J.F. Maher, J. Cui, X. Guo, K.D. Taylor, and R. Azziz FEM1A and FEM1B: novel candidate genes for polycystic ovary syndrome Hum. Reprod., August 29, 2008; (2008) den324v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. Barber, S. J. Golding, C. Alvey, J. A. H. Wass, F. Karpe, S. Franks, and M. I. McCarthy Global Adiposity Rather Than Abnormal Regional Fat Distribution Characterizes Women with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., March 1, 2008; 93(3): 999 - 1004. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Glintborg, K. Hojlund, M. Andersen, J. E. Henriksen, H. Beck-Nielsen, and A. Handberg Soluble CD36 and Risk Markers of Insulin Resistance and Atherosclerosis Are Elevated in Polycystic Ovary Syndrome and Significantly Reduced During Pioglitazone Treatment Diabetes Care, February 1, 2008; 31(2): 328 - 334. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Cascella, S. Palomba, I. De Sio, F. Manguso, F. Giallauria, B. De Simone, D. Tafuri, G. Lombardi, A. Colao, and F. Orio Visceral fat is associated with cardiovascular risk in women with polycystic ovary syndrome Hum. Reprod., January 1, 2008; 23(1): 153 - 159. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Shroff, A. Kerchner, M. Maifeld, E. J. R. Van Beek, D. Jagasia, and A. Dokras Young Obese Women with Polycystic Ovary Syndrome Have Evidence of Early Coronary Atherosclerosis J. Clin. Endocrinol. Metab., December 1, 2007; 92(12): 4609 - 4614. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. J. Moran, M. Noakes, P. M. Clifton, G. A. Wittert, D. P. Belobrajdic, and R. J. Norman C-Reactive Protein before and after Weight Loss in Overweight Women with and without Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 2944 - 2951. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Carmina, S. Bucchieri, A. Esposito, A. Del Puente, P. Mansueto, F. Orio, G. Di Fede, and G. Rini Abdominal Fat Quantity and Distribution in Women with Polycystic Ovary Syndrome and Extent of Its Relation to Insulin Resistance J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2500 - 2505. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Ibanez, A. Jaramillo, G. Enriquez, E. Miro, A. Lopez-Bermejo, D. Dunger, and F. de Zegher Polycystic ovaries after precocious pubarche: relation to prenatal growth Hum. Reprod., February 1, 2007; 22(2): 395 - 400. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. G. Gosman, H. I. Katcher, and R. S. Legro Obesity and the role of gut and adipose hormones in female reproduction Hum. Reprod. Update, September 1, 2006; 12(5): 585 - 601. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Ibanez, K. Ong, D. B. Dunger, and F. d. Zegher Effects of Growth Hormone Treatment on Neutrophil Count in Children Born Small for Gestational Age Pediatrics, May 1, 2006; 117(5): 1868 - 1869. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
